Active substance
Morphine
- SFDA 11
- US FDA 81
- Health Canada 56
- US price lines 19
- NHS prices 32
- WHO EML 2
- Safety 17
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| MORPHINE HCl | 10 mg/ml | Solution for injection · Intrathecal, Intravenous, Intramuscular | 10 Ampoule | SAR 197.50 | NCE · Prescription | LABORATOIRES STEROP NV | Valid |
| MORPHINE SULPHATE BP 10 mg/ml solution for injection | 10 mg/ml | Solution for injection · Parenteral use | 10 Ampoule | SAR 34.85 | Generic · Prescription | MACARTHYS LABORATORIES Ltd T/A MARTINDALE PHARMACEUTICALS | Valid |
| MST Continus 10 mg | 10 mg | Prolonged-release tablet · Oral use | 60 Blister | SAR 47.05 | NCE · Prescription | MUNDIPHARMA MEDICAL COMPANY | Valid |
| MST Continus 30 mg | 30 mg | Prolonged-release tablet · Oral use | 60 Blister | SAR 116.20 | NCE · Prescription | MUNDIPHARMA MEDICAL COMPANY | Valid |
| MST Continus 60 mg | 60 mg | Prolonged-release tablet · Oral use | 60 Blister | SAR 218.90 | NCE · Prescription | MUNDIPHARMA MEDICAL COMPANY | Valid |
| Morphine HCL Kabi | 10 mg/ml | Solution for injection · Intravenous use | 10 Ampoule | SAR 197.50 | NCE · Prescription | Labesfal Laboratorios Almiro, S.A. | Valid |
| Morphine sulfate 10 mg per 5 ml | 2 mg/ml | Oral solution · Oral use | 1 Bottle | SAR 28.65 | Generic · Prescription | Martindale Pharma | Valid |
| Morphine sulfate Kalceks | 10 mg/ml | Solution for injection · Intramuscular and intravenous use | 10 Ampoule | SAR 51.00 | Generic · Prescription | AS Kalceks | Valid |
| Oramorph | 20 mg/ml | Oral solution · Oral use | 1 Dropper Container | SAR 30.35 | NCE · Prescription | L Molteni and C dei F lli Alitti Societa di Esercizio SpA | Valid |
| VERMOR-10MG/ML SOLUTION FOR INJECTION | 10 mg/ml | Solution for injection · Intramuscular and intravenous use | 10 Ampoule | SAR 40.70 | Generic · Prescription | VERVE HUMAN CARE LABORATORIES | Withdrawn by MAH · Not Marketed |
| VERMOR-15MG/ML SOLUTION FOR INJECTION | 15 mg/ml | Solution for injection · Intramuscular and intravenous use | 10 Ampoule | SAR 40.70 | Generic · Prescription | VERVE HUMAN CARE LABORATORIES | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
BURN MANAGEMENT; ENDOMETRIOSIS; SICKLE CELL DISEASE - PAIN MANAGEMENT
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| DURAMORPH PF | 0.5MG/ML; 1MG/ML | injectable · injection | HIKMA PHARMS | Prescription | 18 Sep 1984 |
| INFUMORPH | 10MG/ML; 25MG/ML | injectable · injection | HIKMA PHARMS | Prescription | 18 Sep 1984 |
| MS CONTIN | 30MG; 60MG; 15MG | tablet, extended release · oral | KNOA PHARMA | Prescription | 29 May 1987 |
| MORPHINE SULFATE | 0.5MG/ML | injectable · injection | HOSPIRA | Prescription | 30 Sep 1992 |
| MORPHINE SULFATE | 1MG/ML | injectable · injection | HOSPIRA | Prescription | 30 Sep 1992 |
| MORPHINE SULFATE | 100MG; 200MG | tablet, extended release · oral | RHODES PHARMS | Prescription | 2 Jul 1998 |
| MORPHINE SULFATE | 15MG; 30MG; 60MG | tablet, extended release · oral | RHODES PHARMS | Prescription | 7 Jul 1998 |
| MORPHINE SULFATE | 15MG | tablet, extended release · oral | DAVA PHARMS INC | Prescription | 28 Jan 2000 |
| MORPHINE SULFATE | 100MG; 200MG | tablet, extended release · oral | SPECGX LLC | Prescription | 3 Jul 2003 |
| MORPHINE SULFATE | 15MG; 30MG; 60MG | tablet, extended release · oral | SPECGX LLC | Prescription | 31 Jul 2003 |
| MORPHINE SULFATE | 10MG/5ML; 20MG/5ML; 100MG/5ML | solution · oral | HIKMA PHARMS | Prescription | 17 Mar 2008 |
| MORPHINE SULFATE | 15MG; 30MG | tablet · oral | HIKMA PHARMS | Prescription | 17 Mar 2008 |
| MORPHINE SULFATE | 100MG/5ML | solution · oral | SPECGX LLC | Prescription | 15 Jul 2011 |
| MORPHINE SULFATE | 2MG/ML; 4MG/ML; 8MG/ML; 10MG/ML; 50MG/ML | injectable · injection | HOSPIRA INC | Prescription | 14 Nov 2011 |
| MORPHINE SULFATE | 15MG; 30MG; 60MG; 100MG; 200MG | tablet, extended release · oral | SUN PHARM INDS LTD | Prescription | 11 May 2012 |
| MORPHINE SULFATE | 30MG; 45MG; 60MG; 75MG; 90MG; 120MG | capsule, extended release · oral | ACTAVIS ELIZABETH | Prescription | 16 Jan 2013 |
| MORPHINE SULFATE | 10MG; 20MG; 30MG; 50MG; 60MG; 80MG; 100MG | capsule, extended release · oral | UPSHER SMITH LABS | Prescription | 3 Jun 2013 |
| MORPHINE SULFATE | 2MG/ML (2MG/ML); 4MG/ML (4MG/ML); 10MG/ML (10MG/ML) | solution · intramuscular, intravenous | FRESENIUS KABI USA | Prescription | 30 Oct 2013 |
| MORPHINE SULFATE | 100MG/5ML | solution · oral | TRIS PHARMA INC | Prescription | 12 May 2015 |
| MORPHINE SULFATE | 4MG/ML; 8MG/ML; 10MG/ML | injectable · injection | HIKMA PHARMS | Prescription | 21 May 2015 |
| MORPHINE SULFATE | 100MG/5ML; 10MG/5ML | solution · oral | PHARM ASSOC | Prescription | 14 Nov 2016 |
| MITIGO | 10MG/ML; 25MG/ML | injectable · injection | PIRAMAL CRITICAL | Prescription | 16 Jul 2018 |
| MORPHINE SULFATE | 15MG; 30MG | tablet · oral | UPSHER SMITH LABS | Prescription | 22 Jul 2019 |
| MORPHINE SULFATE | 15MG; 30MG | tablet · oral | ALKEM LABS LTD | Prescription | 3 Dec 2020 |
| MORPHINE SULFATE | 10MG/5ML; 20MG/5ML; 100MG/5ML | solution · oral | WINDER LABS LLC | Prescription | 12 Feb 2021 |
56 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| DOLORAL SIROP | 00614491 | 1 MG / ML | SYRUP · ORAL | LABORATOIRE ATLAS INC |
| DOLORAL SIROP | 00614505 | 5 MG / ML | SYRUP · ORAL | LABORATOIRE ATLAS INC |
| KADIAN | 02184435 | 20 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | BGP PHARMA ULC |
| KADIAN | 02184443 | 50 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | BGP PHARMA ULC |
| KADIAN | 02184451 | 100 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | BGP PHARMA ULC |
| KADIAN | 02242163 | 10 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | BGP PHARMA ULC |
| KADIAN | 02559722 | 200 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | BGP PHARMA ULC |
| M-EDIAT | 02320398 | 5 MG | CAPSULE (IMMEDIATE-RELEASE) · ORAL | ETHYPHARM INC |
| M-EDIAT | 02320428 | 10 MG | CAPSULE (IMMEDIATE-RELEASE) · ORAL | ETHYPHARM INC |
| M-EDIAT | 02320436 | 20 MG | CAPSULE (IMMEDIATE-RELEASE) · ORAL | ETHYPHARM INC |
| M-EDIAT | 02320444 | 30 MG | CAPSULE (IMMEDIATE-RELEASE) · ORAL | ETHYPHARM INC |
| M-ESLON | 02019930 | 10 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | ETHYPHARM INC |
| M-ESLON | 02019949 | 30 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | ETHYPHARM INC |
| M-ESLON | 02019957 | 60 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | ETHYPHARM INC |
| M-ESLON | 02019965 | 100 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | ETHYPHARM INC |
| M-ESLON | 02177749 | 15 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | ETHYPHARM INC |
| M-ESLON | 02177757 | 200 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | ETHYPHARM INC |
| MORPHINE HP 50 | 00617288 | 50 MG / ML | SOLUTION · SUBCUTANEOUS; INTRAMUSCULAR; INTRAVENOUS | SANDOZ CANADA INCORPORATED |
| MORPHINE LP EPIDURAL | 02021048 | 1 MG / ML | SOLUTION · EPIDURAL; INTRAVENOUS; SUBCUTANEOUS | SANDOZ CANADA INCORPORATED |
| MORPHINE LP EPIDURAL | 02021056 | 0.5 MG / ML | SOLUTION · EPIDURAL; INTRAVENOUS; SUBCUTANEOUS | SANDOZ CANADA INCORPORATED |
| MORPHINE SULFATE INJ 10MG/ML USP | 00392588 | 10 MG / ML | SOLUTION · INTRAVENOUS; INTRAMUSCULAR; SUBCUTANEOUS | SANDOZ CANADA INCORPORATED |
| MORPHINE SULFATE INJ 15MG/ML USP | 00392561 | 15 MG / ML | SOLUTION · INTRAMUSCULAR; INTRAVENOUS; SUBCUTANEOUS | SANDOZ CANADA INCORPORATED |
| MORPHINE SULFATE INJECTION | 02500701 | 2 MG / ML | SOLUTION · INTRAMUSCULAR; SUBCUTANEOUS; INTRAVENOUS | JAMP PHARMA CORPORATION |
| MORPHINE SULFATE INJECTION | 02500728 | 10 MG / ML | SOLUTION · SUBCUTANEOUS; INTRAVENOUS; INTRAMUSCULAR | JAMP PHARMA CORPORATION |
| MORPHINE SULFATE INJECTION | 02500736 | 15 MG / ML | SOLUTION · SUBCUTANEOUS; INTRAVENOUS; INTRAMUSCULAR | JAMP PHARMA CORPORATION |
31 more — full table
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | MORPHINE SULF 10 MG/5 ML SOLN | $0.09151 | per ML | 23 Sep 2026 |
| US NADAC | MORPHINE SULF 10 MG/5 ML SOLN | $0.0431 | per ML | 23 Sep 2026 |
| US NADAC | MORPHINE SULF 100 MG/5 ML CONC | $0.45992 | per ML | 23 Sep 2026 |
| US NADAC | MORPHINE SULF 100 MG/5 ML CONC | $0.39203 | per ML | 23 Sep 2026 |
| US NADAC | MORPHINE SULF 100 MG/5 ML CONC | $0.30191 | per ML | 23 Sep 2026 |
| US NADAC | MORPHINE SULF 20 MG/5 ML SOLN | $0.11959 | per ML | 23 Sep 2026 |
| US NADAC | MORPHINE SULF ER 100 MG TABLET | $0.85389 | per EA | 23 Sep 2026 |
| US NADAC | MORPHINE SULF ER 15 MG TABLET | $0.30984 | per EA | 23 Sep 2026 |
| US NADAC | MORPHINE SULF ER 200 MG TABLET | $2.12665 | per EA | 23 Sep 2026 |
| US NADAC | MORPHINE SULF ER 30 MG TABLET | $0.44128 | per EA | 23 Sep 2026 |
| US NADAC | MORPHINE SULF ER 60 MG TABLET | $0.65658 | per EA | 23 Sep 2026 |
| US NADAC | MORPHINE SULFATE 10 MG/ML VIAL | $2.34224 | per ML | 19 Aug 2026 |
| NHS Drug Tariff | Morphine 100mg modified-release capsules | £21.80 | 60 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Morphine 100mg modified-release tablets | £38.50 | 60 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Morphine 10mg modified-release capsules | £3.47 | 60 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Morphine 10mg modified-release tablets | £5.20 | 60 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Morphine 10mg orodispersible tablets sugar free | £7.75 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Morphine 10mg tablets | £5.31 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Morphine 120mg modified-release capsules | £29.15 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Morphine 150mg modified-release capsules | £36.43 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Morphine 15mg modified-release tablets | £9.10 | 60 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Morphine 1mg orodispersible tablets sugar free | £4.75 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Morphine 2.5mg orodispersible tablets sugar free | £5.75 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Morphine 200mg modified-release capsules | £43.60 | 60 capsule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 2.2. Opioid analgesics · core
Pain
Oral > Liquid: 5 mg per 5 mL (morphine hydrochloride or morphine sulfate) (EMLc); 10 mg per 5 mL (morphine hydrochloride or morphine sulfate) | Parenteral > General injections > unspecified: 1 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate) (EMLc); 2 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate) (EMLc); 10 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate) | Oral > Solid > tablet: 10 mg immediate release (morphine sulfate) | Oral > Solid > dosage form: 30 mg slow-release (morphine hydrochloride or morphine sulfate); 200 mg slow-release (morphine hydrochloride or morphine sulfate) (EML); 100 mg slow-release (morphine hydrochloride or morphine sulfate); 60 mg slow-release (morphine hydrochloride or morphine sulfate); 10 mg slow-release (morphine hydrochloride or morphine sulfate); 5 mg slow-release (morphine hydrochloride or morphine sulfate) (EMLc) | Oral > Solid > granules: 20 mg (morphine sulfate); 30 mg (morphine sulfate); 60 mg (morphine sulfate); 100 mg (morphine sulfate); 200 mg (morphine sulfate) (EML) - 1.3. Preoperative medication and sedation for short-term procedures · core
Opioids or related analgesics and agents affecting opioid receptors
Parenteral > General injections > IV: 1 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate) (EMLc); 2 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate) (EMLc); 10 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate)
Safety signals and safety-related labeling changes
- US FDA 22 Dec 2025 DURAMORPH PF — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 22 Dec 2025 INFUMORPH — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 22 Dec 2025 MORPHINE SULFATE — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 22 Dec 2025 MORPHINE SULFATE — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 22 Dec 2025 MORPHINE SULFATE — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 22 Dec 2025 MORPHINE SULFATE — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 22 Dec 2025 MORPHINE SULFATE — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 22 Dec 2025 MS CONTIN — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 15 Dec 2023 MORPHINE SULFATE — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 4 Mar 2021 KADIAN — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 7 Oct 2019 ARYMO ER — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Drug Interactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 7 Oct 2019 EMBEDA — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 7 Oct 2019 MORPHABOND ER — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Drug Interactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 7 Oct 2019 MORPHINE SULFATE — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 7 Oct 2019 MORPHINE SULFATE — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.